Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study (Q46568144)

23 December 2017

title

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study (English)

1 reference

23 December 2017

chronic obstructive pulmonary disease

main subject

pharmacotherapy

0 references

1 reference

7

1 reference

23 December 2017

author name string

Bartolomé R Celli

1

1 reference

23 December 2017

Nicola E Thomas

2

1 reference

23 December 2017

Julie A Anderson

3

1 reference

23 December 2017

Gary T Ferguson

4

1 reference

23 December 2017

Christine R Jenkins

5

1 reference

23 December 2017

Paul W Jones

6

1 reference

23 December 2017

Katharine Knobil

8

1 reference

23 December 2017

Julie C Yates

9

1 reference

23 December 2017

Peter M A Calverley

10

1 reference

23 December 2017

language of work or name

English

0 references

publication date

29 May 2008

1 reference

23 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

23 December 2017

volume

178

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

332-338

1 reference

23 December 2017

Epidemiology and costs of chronic obstructive pulmonary disease.

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Smoking and lung function of Lung Health Study participants after 11 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

The nature of small-airway obstruction in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Gene silencing in severe systemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Standardization of Spirometry, 1994 Update. American Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

The natural history of chronic airflow obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Methodological issues in therapeutic trials of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200712-1869OC

10.1164/RCCM.200712-1869OC

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017